Cargando…
Effectiveness and Tolerability of Once-Weekly GLP-1 Receptor Agonists in Clinical Practice: A Focus on Switching Between Once-Weekly Molecules in Type 2 Diabetes
AIMS: This study aims to evaluate the effectiveness and tolerability of once-weekly glucagon-like peptide receptor agonists (OW GLP-1RAs) and to assess the clinical benefits of switching from one GLP-1RA to another (switchers) in a routine clinical setting. MATERIALS AND METHODS: This is a retrospec...
Autores principales: | Di Dalmazi, Giulia, Coluzzi, Sara, Baldassarre, Maria Pompea Antonia, Ghit, Amr, Graziano, Giusi, Rossi, Maria Chiara, Ciappini, Beatrice, Milo, Marica, Carrieri, Federica, Nicolucci, Antonio, Consoli, Agostino, Formoso, Gloria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335857/ https://www.ncbi.nlm.nih.gov/pubmed/35909534 http://dx.doi.org/10.3389/fendo.2022.892702 |
Ejemplares similares
-
An overview of the once‐weekly GLP‐1 receptor agonists from the pharmacist’s perspective
por: Patel, Dhiren
Publicado: (2020) -
Safety and tolerability of once‐weekly GLP‐1 receptor agonists in type 2 diabetes
por: Trujillo, Jennifer
Publicado: (2020) -
Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany
por: Qiao, Qing, et al.
Publicado: (2016) -
Cardiovascular safety outcomes of once‐weekly GLP‐1 receptor agonists in people with type 2 diabetes
por: Goldman, Jennifer D.
Publicado: (2020) -
Energy Balance in Hypothalamic Obesity in Response to Treatment with a Once-Weekly GLP-1 Receptor Agonist
por: Shoemaker, Ashley H., et al.
Publicado: (2022)